Comparative Pharmacology
Head-to-head clinical analysis: KEFLIN versus VELOSEF 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFLIN versus VELOSEF 125.
KEFLIN vs VELOSEF '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation, leading to cell lysis.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
1-2 g IV/IM every 4-6 hours; maximum 12 g/day.
500 mg orally every 6 hours for uncomplicated infections; 1 g orally every 6 hours for more severe infections.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour (normal renal function); prolonged to 2-3 hours in anuria. Clinically, dosing every 6 hours is recommended.
Terminal elimination half-life: 0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in severe renal impairment (CrCl <10 mL/min)
Renal: 70-80% unchanged via glomerular filtration and tubular secretion; biliary: minimal (<5%); fecal: <1%.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic